ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)

Summary

This is a prospective, single-center, phase 1 safety study to investigate the safety, tolerability, seizure control, and quality of life in participants with medically-refractory epilepsy who failed epilepsy surgery. These participants will have continued seizures despite being at least 3 months post-epilepsy surgery (resective surgery with an intent to cure).

Timeline

Start

2018-07-31

Primary completion

2022-08-22

Completion

2022-12-31

Drugs

Indications